Chronic obstructive pulmonary disease. Mortality and mortality reduction

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Chronic obstructive pulmonary disease (COPD) affects an estimated 15 million Americans and is the fourth most common cause of death in the US. Despite an improved understanding of the disease, treatment has changed little over the past 20 to 30 years and COPD remains a major health problem worldwide. Smoking is the major risk factor for COPD, accounting for some 90% of cases. Therefore, smoking cessation remains the most important intervention. Other available pharmacotherapeutic options include corticosteroids, bronchodilators, antibiotics for the treatment of acute exacerbations, mucokinetic agents, and oxygen for the advanced stages of the disease. Recent data investigating the use of dornase alfa (recombinant human deoxyribonuclease I) in patients with acute exacerbations of CORD were disappointing and failed to demonstrate a mortality benefit. While it is likely that ongoing research will optimise the use of older agents and identify new treatment options for patients with COPD, smoking cessation will probably remain the most important intervention and should be a key focus of future initiatives aimed at controlling this disease.

Original languageEnglish (US)
Pages (from-to)55-61
Number of pages7
JournalDrugs
Volume52
Issue numberSUPPL. 2
StatePublished - Sep 11 1996
Externally publishedYes

Fingerprint

Pulmonary diseases
Chronic Obstructive Pulmonary Disease
Mortality
Smoking Cessation
Bronchodilator Agents
Medical problems
Cause of Death
Adrenal Cortex Hormones
Therapeutics
Smoking
Oxygen
Anti-Bacterial Agents
Research
dornase alfa

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

@article{8d07be61e28d428689198cefdef72df8,
title = "Chronic obstructive pulmonary disease. Mortality and mortality reduction",
abstract = "Chronic obstructive pulmonary disease (COPD) affects an estimated 15 million Americans and is the fourth most common cause of death in the US. Despite an improved understanding of the disease, treatment has changed little over the past 20 to 30 years and COPD remains a major health problem worldwide. Smoking is the major risk factor for COPD, accounting for some 90{\%} of cases. Therefore, smoking cessation remains the most important intervention. Other available pharmacotherapeutic options include corticosteroids, bronchodilators, antibiotics for the treatment of acute exacerbations, mucokinetic agents, and oxygen for the advanced stages of the disease. Recent data investigating the use of dornase alfa (recombinant human deoxyribonuclease I) in patients with acute exacerbations of CORD were disappointing and failed to demonstrate a mortality benefit. While it is likely that ongoing research will optimise the use of older agents and identify new treatment options for patients with COPD, smoking cessation will probably remain the most important intervention and should be a key focus of future initiatives aimed at controlling this disease.",
author = "Stanley Fiel",
year = "1996",
month = "9",
day = "11",
language = "English (US)",
volume = "52",
pages = "55--61",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "SUPPL. 2",

}

Chronic obstructive pulmonary disease. Mortality and mortality reduction. / Fiel, Stanley.

In: Drugs, Vol. 52, No. SUPPL. 2, 11.09.1996, p. 55-61.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chronic obstructive pulmonary disease. Mortality and mortality reduction

AU - Fiel, Stanley

PY - 1996/9/11

Y1 - 1996/9/11

N2 - Chronic obstructive pulmonary disease (COPD) affects an estimated 15 million Americans and is the fourth most common cause of death in the US. Despite an improved understanding of the disease, treatment has changed little over the past 20 to 30 years and COPD remains a major health problem worldwide. Smoking is the major risk factor for COPD, accounting for some 90% of cases. Therefore, smoking cessation remains the most important intervention. Other available pharmacotherapeutic options include corticosteroids, bronchodilators, antibiotics for the treatment of acute exacerbations, mucokinetic agents, and oxygen for the advanced stages of the disease. Recent data investigating the use of dornase alfa (recombinant human deoxyribonuclease I) in patients with acute exacerbations of CORD were disappointing and failed to demonstrate a mortality benefit. While it is likely that ongoing research will optimise the use of older agents and identify new treatment options for patients with COPD, smoking cessation will probably remain the most important intervention and should be a key focus of future initiatives aimed at controlling this disease.

AB - Chronic obstructive pulmonary disease (COPD) affects an estimated 15 million Americans and is the fourth most common cause of death in the US. Despite an improved understanding of the disease, treatment has changed little over the past 20 to 30 years and COPD remains a major health problem worldwide. Smoking is the major risk factor for COPD, accounting for some 90% of cases. Therefore, smoking cessation remains the most important intervention. Other available pharmacotherapeutic options include corticosteroids, bronchodilators, antibiotics for the treatment of acute exacerbations, mucokinetic agents, and oxygen for the advanced stages of the disease. Recent data investigating the use of dornase alfa (recombinant human deoxyribonuclease I) in patients with acute exacerbations of CORD were disappointing and failed to demonstrate a mortality benefit. While it is likely that ongoing research will optimise the use of older agents and identify new treatment options for patients with COPD, smoking cessation will probably remain the most important intervention and should be a key focus of future initiatives aimed at controlling this disease.

UR - http://www.scopus.com/inward/record.url?scp=0029821505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029821505&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 55

EP - 61

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - SUPPL. 2

ER -